BMS-1

BMS-1 is a small molecule inhibitor developed by Bristol Myers Squibb and is primarily described in preclinical research literature as a selective inhibitor of the PD-1/PD-L1 interaction. It acts by blocking the immune checkpoint pathway mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, thereby promoting immune system activation against cancer cells. This mechanism is distinct from monoclonal antibody therapies targeting PD-1/PD-L1. BMS-1 has been investigated mostly in vitro and in animal models for its potential as an antitumor agent and as an immunomodulatory therapy, but there is no evidence it has advanced to clinical trials or commercial use.